|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0017428,
umls-concept:C0066357,
umls-concept:C0205179,
umls-concept:C0205210,
umls-concept:C0205314,
umls-concept:C0679622,
umls-concept:C0871261,
umls-concept:C1527249,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1882417,
umls-concept:C2698872,
umls-concept:C2911692
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2003-5-9
|
|
pubmed:abstractText |
Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer. Methylenetetrahydrofolate reductase (MTHFR) could play an important role in the action of 5-FU, an inhibitor of thymidylate synthetase, by converting 5,10-methylenetetrahydrofolate, a substrate of thymidylate synthetase, to 5-methyltetrahydrofolate. A polymorphism in MTHFR (677 C-->T; A222V) reduces enzyme activity and presumably increases the level of 5,10-methylenetetrahydrofolate. This increase would be expected to correlate with an improved response to 5-FU. The aim of the present study was to investigate the association between the MTHFR polymorphism and response to 5-FU and other fluoropyrimidines in patients with metastatic colorectal cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1611-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12738713-Adenocarcinoma,
pubmed-meshheading:12738713-Adult,
pubmed-meshheading:12738713-Aged,
pubmed-meshheading:12738713-Alleles,
pubmed-meshheading:12738713-Antineoplastic Agents,
pubmed-meshheading:12738713-Colorectal Neoplasms,
pubmed-meshheading:12738713-DNA, Neoplasm,
pubmed-meshheading:12738713-Deoxycytidine,
pubmed-meshheading:12738713-Female,
pubmed-meshheading:12738713-Fluorouracil,
pubmed-meshheading:12738713-Genotype,
pubmed-meshheading:12738713-Humans,
pubmed-meshheading:12738713-Male,
pubmed-meshheading:12738713-Methylenetetrahydrofolate Reductase (NADPH2),
pubmed-meshheading:12738713-Middle Aged,
pubmed-meshheading:12738713-Neoplasm Staging,
pubmed-meshheading:12738713-Polymorphism, Genetic,
pubmed-meshheading:12738713-Predictive Value of Tests
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
|
|
pubmed:affiliation |
Department of Medicine, McGill University, Montreal, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
